Page last updated: 2024-12-06
iosulamide
Description
Iosulamide is a sulfonamide derivative that acts as a carbonic anhydrase inhibitor. Its synthesis involves a multi-step process, typically starting with the reaction of an aromatic amine with a sulfonyl chloride. Iosulamide exhibits diuretic properties and has been studied for its potential therapeutic applications in conditions such as glaucoma and epilepsy. Its mechanism of action involves blocking the enzyme carbonic anhydrase, which plays a role in fluid and electrolyte balance. Research on iosulamide has focused on understanding its pharmacological properties, potential clinical uses, and its interactions with other drugs.'
iosulamide: RN given refers to parent cpd; see also iosulamide meglumine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 44557 |
CHEMBL ID | 1615440 |
SCHEMBL ID | 2109419 |
MeSH ID | M0092610 |
Synonyms (18)
Synonym |
iosulamide |
3-[acetyl(ethyl)amino]-5-[3-[3-[3-[acetyl(ethyl)amino]-5-carboxy-2,4,6-triiodoanilino]-3-oxopropyl]sulfonylpropanoylamino]-2,4,6-triiodobenzoic acid |
iosulamido |
ip251kpi8e , |
einecs 245-487-2 |
iosulamido [inn-spanish] |
23205-04-1 |
iosulamidum |
unii-ip251kpi8e |
iosulamide [usan:inn] |
iosulamidum [inn-latin] |
iosulamide [inn] |
3,3'-(sulfonylbis(ethylenecarbonylimino))bis(5-(n-ethylacetamino)-2,4,6-triiodobenzoic acid) |
benzoic acid, 3,3'-(sulfonylbis((1-oxo-3,1-propanediyl)imino))bis(5-(acetylethylamino)-2,4,6-triiodo- |
SCHEMBL2109419 |
CHEMBL1615440 |
DTXSID00177786 |
Q27280833 |
Research Excerpts
Overview
Iosulamide is a bis-benzoic analogue of metrizoate. It shows clear advantages in animal tests over meglumine iodipamide.
Pharmacokinetics
Research
Studies (2)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |